Bioverativ Inc. (BIVV)

104.98 +0.33 (+0.315%)

IEX Real-Time Price

March 8, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 104.65

Price Open 104.97

Volume: 791,050

Avg Volume: 2.72M

Market Cap: 11.36B

P/E Ratio 38.17

52 Wk Range 48.14-105.01



BIVV Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-02-15
107.95M
2.76M
0.67
2.55%

2018-01-31
107.95M
2.3M
0.67
2.13%

2018-01-12
107.95M
9.6M
8.79
8.89%

2017-12-29
107.93M
8.54M
7.28
7.91%




BIVV Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-02
Q1 2018
N/A
0.83 (1)
0.00
0.00

2018-02-13
Q4 2017
AMC
0.72 (2)
0.76
0.01

2018-01-25
Q4 2017
N/A
0.48 (2)
0.76
0.01

2017-10-26
Q3 2017
AMC
0.55 (2)
0.76
0.01

News

Sangamo Therapeutics Part III: Elucidating The Prospects Of Amyotrophic Lateral Sclerosis (2018-03-09 13:30 SeekingAlpha)

The successful investor is usually an individual who is inherently interested in business problems. - The Father of Growth Investing (Philip Fisher) In the past 3-month, the shares of Sangamo Therapeutics (NASDAQ: SGMO ) - a gene-editing bioscience focusing on the innovation and launch o…

 

By The Numbers: Profitable Stocks With Reasonable Valuations And Rising Earnings Expectations (2018-03-08 08:12 SeekingAlpha)

Investing is always a matter of probabilities as opposed to certainties. There is no way to tell for certain how a specific asset or an investment strategy is going to perform in a particular period. On the other hand, statistical data shows that companies offering some specific quantitative a…

 

Sangamo Therapeutics - Part II: Is There A Hidden Asset In Play? (2018-03-08 07:05 SeekingAlpha)

Never promote someone who hasnt made some bad mistakes, because if you do, you are promoting someone who has never done anything. - The Father of Growth Investing (Philip Fisher) On March 08, 2018, the shares of Sangamo Therapeutics (NASDAQ: SGMO ), a gene-editing bioscience, tra…

 

Your Daily Pharma Scoop: Genocea Surges, Gilead's Biktarvy, GlaxoSmithKline's Vaccine Succeeds In Late-Stage Study (2018-03-07 08:00 SeekingAlpha)

Analysis of top Seeking Alpha coverage: Genocea Biosciences Today, we will discuss Genocea Biosciences (GNCA), which is up sharply after a bullish note from Cantor Fitzgerald. In early trading, GNCA shares were up nearly 10%, offsetting some of the losses the company has incurred in 2018. Ye…

 

Bioverativ launches late-stage development of BIVV009 in rare blood disease (2018-03-06 08:24 SeekingAlpha)

Dosing is underway in a Phase 3 program assessing Bioverativ's (NASDAQ: BIVV ) BIVV009 in patients with cold agglutinin disease (CAgD); a rare autoimmune disorder in which the body's immune system destroys red blood cells. More news on: Bioverativ Inc., Healthcare stocks news, R…

 


Statistics

Shares Outstanding: 108.22M

Top 15 Institution Percent: 63.80

Price To Sales: 9.69

Price To Book: 12.62

Revenue: 1.17B

Gross Profit: 888.90M

Cash: 1.16B

Debt: N/A

Return On Assets: 28.99

Return On Equity: 46.08

Profit Margin: 29.86

Price History

Beta: 6.60

50-day Moving Avg: 88.36

200-day Moving Avg: 64.80

YTD Change: 91.05

5-day Change: 0.24

1-month Change: 1.43

3-month Change: 108.92

6-month Change: 88.78

1-year Change: 100.31

Revenue Per Share: 11.00

Revenue Per Employee: 2540217.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Bioverativ Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.bioverativ.com

Bioverativ Inc is a global biotechnology company which focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Its products includes Eloctate and Alprolix.